Drug Information Update - Webinar March 28 on Alzheimer's Disease with FDA/CDER's Dr. Russell Katz

The Division of Drug Information (DDI) is CDER's focal point for public inquiries. We serve the public by providing information on human drug products and drug product regulation by FDA.

---

On Thursday, March 28, from 1:00 – 2:00 p.m. EDT, FDA/CDER’s Office of Medical Policy will host a webinar with Division of Neurology Products director, Dr. Russell Katz, on a new draft guidance for industry Alzheimer’s Disease: Developing Drugs For The Treatment Of Early Stage Disease.  

Webinar information is posted on: http://www.fda.gov/Drugs/ucm345077.htm 

To view the draft guidance, visit: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM338287.pdf

Webinar Online-Access Instructions:

·       Access link: https://collaboration.fda.gov/guidancewebinars

·       After following the link, enter as a guest and provide your FULL NAME and organization (i.e. "John Smith - FDA/CBER"). The host will then allow you to enter.

·       Audio will broadcast from your computer speakers.

·       Closed captioning will be provided.

·       Questions/Comments can be submitted live via a Q/A chat window.

·       If you experience technical difficulties, email Jeffery.Rexrode@fda.hhs.gov for assistance.